Skip to main content

OrbusNeich Medical Group Holdings Limited (6929.HK)

Hong Kong Stock Exchange Healthcare Medical - Instruments & SuppliesView data quality →
56.7Fair

ValueMarkers Composite Index

Top 62%#17,017 of 44,707
Undervalued

82% below intrinsic value ($20)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.21
Investigate
Altman
47.76
Safe
DCF Value
$20
Undervalued
ROIC
8.4%
Adequate
P/E
9.9
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

OrbusNeich Medical Group Holdings Limited (6929.HK) — VMCI valuation read

Across 120 indicators, OrbusNeich Medical Group Holdings Limited (6929.HK) lands at VMCI 57/100. The Healthcare sector median is 50, so the 7-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 6929.HK in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 6929.HK trades at 15.0x earnings, 17% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 3.0x is the rate-sensitivity line to watch for 6929.HK on the trailing balance sheet.

6929.HK rose 2.2% over the trailing 7 days, with a -10.0% read on a 30-day basis.

OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company was founded in 2001 and is headquartered in Shatin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.

CEO: David Chien1,331 employeesHKorbusneich.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 6929.HK’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.